Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6127400 | 0.85 | NR3C2 (1.00) | NR3C2 | |
| SCHEMBL4536519 | 0.84 | NR3C2 (1.00) | NR3C2 | |
| SCHEMBL4533804 | 0.84 | NR3C2 (1.00) | NR3C2 | |
| SCHEMBL6127425 | 0.84 | NR3C2 (1.00) | NR3C2 | |
| SCHEMBL6127493 | 0.82 | NR3C2 (1.00) | NR3C2 | |
| SCHEMBL13719711 | 0.81 | NR3C2 (1.00) | NR3C2 | |
| SCHEMBL4536428 | 0.81 | NR3C2 (1.00) | NR3C2 | |
| SCHEMBL4536580 | 0.81 | NR3C2 (0.68) | NR3C2 | |
| SCHEMBL10086061 | 0.77 | NR3C2 (1.00) | NR3C2 | |
| SCHEMBL6127506 | 0.76 | NR3C2 (1.00) | NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490606-B1 | ANTAGONIST OF MINERALOCORTICOID RECEPTOR FOR THE TREATMENT OF OSTEOARTHRITIS | INST NAT SANTE RECH MED (FR) | 2024-01-17 | — | — | EP | disclosed |
| EP-3362095-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHOROIDAL NEOVASCULARISATION | INST NAT SANTE RECH MED (FR) | 2020-11-25 | — | — | EP | disclosed |
| US-20190262363-A1 | ANTAGONIST OF MINERALOCORTICOID RECEPTOR FOR THE TREATMENT OF OSTEOARTHRITIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-08-29 | — | — | US | disclosed |
| WO-2018019843-A1 | ANTAGONIST OF MINERALOCORTICOID RECEPTOR FOR THE TREATMENT OF OSTEOARTHRITIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-02-01 | — | — | WO | disclosed |
| US-20170273992-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING | Universite De Paris (FR) | 2017-09-28 | — | — | US | disclosed |
| US-9730948-B2 | Pharmaceutical compositions for preventing glucocorticoid-induced skin thinning | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-15 | — | — | US | disclosed |
| WO-2017064121-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHOROIDAL NEOVASCULARISATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-04-20 | — | — | WO | disclosed |
| US-20160136183-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING | Universite De Paris (FR) | 2016-05-19 | — | — | US | disclosed |
| WO-2016005424-A1 | METHODS FOR ASSESSING MINERALOCORTICOID RECEPTOR ACTIVATION IN ADIPOSE TISSUE OF A SUBJECT AND TREATING METABOLIC SYNDROME | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-01-14 | — | — | WO | disclosed |
| WO-2014202744-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-12-24 | — | — | WO | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| EP-2638012-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| WO-2012064631-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064631-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262363-A1 | ANTAGONIST OF MINERALOCORTICOID RECEPTOR FOR THE TREATMENT OF OSTEOARTHRITIS | MC2R, NR3C2, ADIPOR1 | NR3C2 2/4885 |
| US-20160136183-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING | NR3C1, NR3C2, MC2R | NR3C2 2/4885 |
| US-20170273992-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING | NR3C1, NR3C2, MC2R | NR3C2 2/4885 |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, MC2R, AVPR2 | NR3C2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.